<table className="table">
  <caption>
    <p>
      Characteristics of Biologic Agents Indicated to Treat Severe Asthma
    </p>
  </caption>
  <thead>
    <tr>
      <th rowSpan="1" colSpan="1">
        <p>
          Biologic Agent
          <sup>
            a
          </sup>
        </p>
      </th>
      <th rowSpan="1" colSpan="1">
        <p>
          Target
        </p>
      </th>
      <th rowSpan="1" colSpan="1">
        <p>
          Guidelines
          <sup>
            b
          </sup>
        </p>
      </th>
      <th rowSpan="1" colSpan="1">
        <p>
          Formulation
        </p>
      </th>
      <th rowSpan="1" colSpan="1">
        <p>
          Home Use
        </p>
      </th>
      <th rowSpan="1" colSpan="1">
        <p>
          Adverse Effects
        </p>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr className="group_1-1 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          Omalizumab
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          IgE
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Severe asthma, IgE 30 to 700 U/mL (30-700 kU/L) and atopy
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Subcutaneous injection
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Yes
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Anaphylaxis, increased risk of malignancy
        </p>
      </td>
    </tr>
    <tr className="group_1-2 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          Mepolizumab
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          IL-5
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Severe asthma, absolute eosinophils &gt;150/μL (0.15 × 10
          <sup>
            9
          </sup>
          /L)
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Subcutaneous injection
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Yes
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Hypersensitivity reactions, headache,
        </p>
        <p>
          helminth infections
        </p>
      </td>
    </tr>
    <tr className="group_1-3 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          Reslizumab
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          IL-5
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Severe asthma, absolute eosinophils &gt;400/μL (0.4 × 10
          <sup>
            9
          </sup>
          /L)
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Intravenous infusion
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          No
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Anaphylaxis, headache, helminth infections
        </p>
      </td>
    </tr>
    <tr className="group_1-4 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          Benralizumab
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          IL-5
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Severe asthma, absolute eosinophils &gt;150/μL (0.15 × 10
          <sup>
            9
          </sup>
          /L)
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Subcutaneous injection
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Yes
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Hypersensitivity reactions, helminth infections
        </p>
      </td>
    </tr>
    <tr className="group_1-5 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          Dupilumab
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          IL-4, IL-13
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Moderate to severe asthma, absolute eosinophils &gt;150/μL (0.15 × 10
          <sup>
            9
          </sup>
          /L) or dependence on systemic glucocorticoids
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Subcutaneous injection
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Yes
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Hypersensitivity reactions, helminth infections
        </p>
      </td>
    </tr>
    <tr className="group_1-6 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          Tezepelumab
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          TSLP
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Severe asthma, add-on therapy
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Subcutaneous injection
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Yes
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Hypersensitivity reactions
        </p>
      </td>
    </tr>
  </tbody>
</table>
